Development of an MRI contrast agent for both detection and inhibition of the amyloid-β fibrillation process

9Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

Abstract

A curcumin derivative conjugated with Gd-DO3A (Gd-DO3A-Comp.B) was synthesised as an MRI contrast agent for detecting the amyloid-β (Aβ) fibrillation process. Gd-DO3A-Comp.B inhibited Aβ aggregation significantly and detected the fibril growth at 20 μM of Aβ with 10 μM of probe concentration by T1-weighted MR imaging.

Cite

CITATION STYLE

APA

Utomo, R. Y., Okada, S., Sumiyoshi, A., Aoki, I., & Nakamura, H. (2022). Development of an MRI contrast agent for both detection and inhibition of the amyloid-β fibrillation process. RSC Advances, 12(8), 5027–5030. https://doi.org/10.1039/d2ra00614f

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free